Is Novolin a Long-Acting Insulin?
No, Novolin is NOT a long-acting insulin—it is available as either a short-acting (regular) insulin or an intermediate-acting insulin (NPH), depending on the specific formulation.
Novolin Formulations and Duration of Action
Novolin R (Regular Human Insulin)
- Short-acting insulin with rapid onset but brief duration 1
- Used primarily for prandial (mealtime) coverage 2, 3
- Pharmacodynamic profile shows it acts as a rapid-acting formulation, not long-acting 2
Novolin 70/30 (Mixed Formulation)
- Contains 70% NPH (intermediate-acting) and 30% Regular insulin 1
- Classified as intermediate-acting insulin 1
- Onset of action: approximately 30 minutes after injection 1
- Peak effect: between 2 and 12 hours 1
- Duration: up to 24 hours (but this does NOT make it long-acting by clinical classification) 1
Novolin N (NPH)
- Intermediate-acting basal insulin 1
- Used for basal glucose control but has shorter duration than true long-acting analogs 4
Clinical Context: What Defines Long-Acting Insulin
According to the 2025 American Diabetes Association guidelines, true long-acting basal insulin analogs include 4:
- U-100 glargine and detemir (first-generation long-acting)
- U-300 glargine and degludec (longer-acting with lower nocturnal hypoglycemia risk)
Key Distinction
- NPH insulin (like Novolin N) can achieve fasting glucose goals but has higher risk of level 2 hypoglycemia and nocturnal hypoglycemia compared to true long-acting analogs 4
- The guidelines explicitly distinguish NPH as an option for basal coverage but note the superior safety profile of long-acting analogs 4
Clinical Pitfalls to Avoid
- Do not confuse duration with classification: While Novolin 70/30 can last up to 24 hours, its pharmacodynamic profile with pronounced peak effect (2-12 hours) makes it intermediate-acting, not long-acting 1
- Novolin R is NOT interchangeable with long-acting insulins—it is specifically designed for prandial use 2, 3, 5
- When patients need true basal insulin coverage with minimal hypoglycemia risk, long-acting analogs are preferred over NPH-containing formulations like Novolin products 4